Home » Opinion » Foreign Views
Corporate secrecy preceded US weed killer crisis
Print Edition
As the US growing season entered its peak this summer, farmers began posting startling pictures on social media: fields of beans, peach orchards and vegetable gardens withering away.
The photographs served as early warnings of a crisis that has damaged millions of acres of farmland. New versions of the herbicide dicamba developed by Monsanto and BASF, according to farmers, have drifted across fields to crops unable to withstand it, a charge authorities are investigating.
As the crisis intensifies, new details provided to Reuters by independent researchers and regulators, and previously unreported testimony by a company employee, demonstrate the unusual way Monsanto introduced its product.
Typically, when a company develops a new agricultural product, it commissions its own tests and shares the results and data with regulators. It also provides product samples to universities for additional scrutiny. Regulators and university researchers then work together to determine the safety of the product.
In this case, Monsanto denied requests by university researchers to study its XtendiMax with VaporGrip for volatility — a measure of its tendency to vaporize and drift across fields.
The researchers interviewed by Reuters said Monsanto provided samples of XtendiMax before it was approved by the EPA. However, the samples came with contracts that explicitly forbade volatility testing. The researchers declined to provide Reuters a copy of the Monsanto contracts, saying they were not authorized to do so.
Monsanto’s Vice President of Global Strategy, Scott Partridge, said the company prevented the testing because it was unnecessary. He said the company believed the product was less volatile than a previous dicamba formula that researchers found could be used safely.
Monsanto employee Boyd Carey, an agronomist, laid out the company’s rationale for blocking the independent research at a hearing of the Arkansas Plant Board’s Pesticide Committee in the summer of 2016. A meeting summary by the Arkansas Legislature’s Joint Budget Committee described Carey’s testimony as follows: “Boyd Carey is on record on August 8 stating that neither the University of Arkansas nor any other university was given the opportunity to test VaporGrip in fear that the results may jeopardize the federal label.”
Efforts to reach Carey were not successful. Monsanto declined to comment on his testimony. To be sure, complaints about damaged crops are still under investigation and there is no evidence that independent testing of XtendiMax’s volatility would have altered the course of the crisis. But it would have given regulators a more complete picture of the formula’s properties as they decided if and how to let farmers use it, agriculture experts said.
In the end, the EPA approved the product without the added testing in September. It said it made its decision after reviewing company-supplied data, including some measuring volatility.
Concerned about damage
“EPA’s analysis of the data has shown reduced volatility potential with newer formulations,” the EPA said in a July 27 statement. However, EPA spokeswoman Amy Graham told Reuters the agency is “very concerned about the recent reports of crop damage” and is reviewing restrictions on dicamba labels.
Monsanto Chief Technology Officer Robert Fraley said, “We firmly believe that our product if applied according to the instructions on the label will not move off target and damage anyone.”
Companies can limit independent testing because the substances are proprietary. When samples are provided to researchers, lawyers hammer out contracts detailing how testing will be conducted and results will be handled, but rarely do agreements limit what the products can be tested for, according to researchers interviewed by Reuters.
For instance, BASF, which introduced its rival herbicide, Engenia, around the same time, said it allowed several university researchers to evaluate its “off-target impact and application parameters.”
The EPA did not answer questions about whether it noticed a lack of input from university researchers about XtendiMax’s volatility or whether it requested such testing. It also did not address whether the lack of independent research played into its decision to give the product an abridged two-year registration, less than the 20 years experts say is more common. The agency did the same for BASF’s Engenia.
“The EPA placed time limits on the registration to allow the agency to either let it expire or to easily make the necessary changes in the registration if there are problems,” Graham, the EPA spokeswoman, said.
The article is from Reuters. Shanghai Daily condensed the article.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
